15 New England Executive Park
Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, NS2, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.
FOUNDERS: Thomas A. Jordan and John E. Dowling
CEO: Todd C. Brady
CMO: David J. Clark
CFO: Stephen Tulipano
Please click here for Aldeyra job opportunities..
Please click here for clinical trial information..